ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Otsuka and Bristol-Myers Squibb side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

OtsukaBristol-Myers Squibb
studies on the registry7842,184
open to participants now55155
phase 3 studies under way3182
reach primary completion within a year2367
programswith a study of their own in two years2557+9 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOtsukaBristol-Myers Squibb
Phase 1

Otsuka: 12 of its 25 programs at phase 1

  1. VIS171phase 1
  2. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  3. ARC-02phase 1
  4. HBM7020phase 1
  5. SEP-380135phase 1

and 7 more — sign in to see them all

48%

Bristol-Myers Squibb: 17 of its 57 programs at phase 1

  1. BMS-986454phase 1
  2. orevandrodegphase 1
  3. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1
  4. BMS-985521phase 1
  5. BMS-986485phase 1

and 12 more — sign in to see them all

30%
Phase 2

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%

Bristol-Myers Squibb: 17 of its 57 programs at phase 2

  1. irafamdastatphase 2
  2. moponetugphase 2
  3. delocamtenphase 2
  4. imzokitugphase 2
  5. Cyclophosphamidephase 2

and 12 more — sign in to see them all

30%
Phase 3

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%

Bristol-Myers Squibb: 16 of its 57 programs at phase 3

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. golcadomidephase 3
  5. zolacabtagene autoleucelphase 3

and 11 more — sign in to see them all

28%
Approved, new studies

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%

Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. deucravacitinibapproved, new study
  4. Nivolumabapproved, new study
  5. trospium chlorideapproved, new study

and 2 more — sign in to see them all

12%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Otsuka8 readouts · 3 phase 3·

Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
Bristol-Myers Squibb22 readouts · 7 phase 3

Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. trospiumapproved, new study · Nov 24 · NCT06585787
  2. xanomelineapproved, new study · Nov 24 · NCT06585787

Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. actinium AC-225 dotatatephase 3 · Dec 0 · NCT05477576
  2. navlimetostatphase 3 · Dec 5 · NCT07777133
  3. delocamtenphase 2 · Dec 14 · NCT06122779
  4. golcadomidephase 3 · Dec 14 · NCT07763418
  5. moponetugphase 2 · Dec 17 · NCT06268886

and 2 more — sign in to see them all

Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mezigdomidephase 3 · Jan 10 · NCT05519085

Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. Actinium Ac 225 SSTR2-targeted Agent RYZ401phase 1 · Feb 0 · NCT07165132
  2. Nivolumabapproved, new study · Feb 5 · NCT06946797
  3. repotrectinibphase 3 · Feb 16 · NCT06140836

Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion

  1. trospium chlorideapproved, new study · Mar 29 · NCT07063342
·

Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion

  1. elranatamabphase 2 · May 31 · NCT06988488

Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion

  1. BMS-986533phase 1 · Jun 1 · NCT07629999
  2. BMS-986485phase 1 · Jun 8 · NCT07887763
  3. BMS-986454phase 1 · Jun 28 · NCT07171983

Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion

  1. zolacabtagene autoleucelphase 3 · Jul 15 · NCT06220201

Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. atigotatugphase 3 · Aug 17 · NCT06646276

Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. dezandrodegphase 3 · Sep 12 · NCT06764485

Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion

  1. BMS-986488phase 1 · Oct 15 · NCT06764771
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 1

  • SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084

Primary completion later 3

Bristol-Myers Squibb

New programs 5

  • BMS-986548phase 2 · first study · Nov 10
  • BMS-986485phase 1 · first study · Oct 14
  • BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
  • RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
  • BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionOtsukaBristol-Myers Squibb
Carcinoma, Non-Small-Cell Lungboth · compare here

Otsuka in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. zipalertinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Carcinoma, Non-Small-Cell Lung in search

Bristol-Myers Squibb in Carcinoma, Non-Small-Cell Lung: 11 programs

  1. navlimetostatphase 3
  2. pumitamigphase 3
  3. adagrasibphase 3
  4. izalontamab brengitecanphase 3
  5. repotrectinibphase 3

and 6 more — sign in to see them all

Their studies: Bristol-Myers Squibb’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsboth · compare here

Otsuka in Breast Neoplasms: 1 program

  1. futibatinibphase 3

Their studies: Otsuka’s studies of Breast Neoplasms in search

Bristol-Myers Squibb in Breast Neoplasms: 4 programs

  1. pumitamigphase 3
  2. izalontamab brengitecanphase 3
  3. actinium AC-225 dotatatephase 3
  4. Cyclophosphamidephase 2

Their studies: Bristol-Myers Squibb’s studies of Breast Neoplasms in search

Schizophreniaboth · compare here

Otsuka in Schizophrenia: 2 programs

  1. ulotarontphase 3
  2. SEP-380135phase 1

Their studies: Otsuka’s studies of Schizophrenia in search

Bristol-Myers Squibb in Schizophrenia: 3 programs

  1. xanomelineapproved, new study
  2. trospiumapproved, new study
  3. trospium chlorideapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Schizophrenia in search

Arthritis, Rheumatoidboth · compare here

Otsuka in Arthritis, Rheumatoid: 1 program

  1. HBM7020phase 1

Their studies: Otsuka’s studies of Arthritis, Rheumatoid in search

Bristol-Myers Squibb in Arthritis, Rheumatoid: 3 programs

  1. tocilizumabphase 3
  2. BMS-986528phase 2
  3. BMS-986454phase 1

Their studies: Bristol-Myers Squibb’s studies of Arthritis, Rheumatoid in search

Kidney Failure, Chronicboth · compare here

Otsuka in Kidney Failure, Chronic: 1 program

  1. Tolvaptanapproved, new study

Their studies: Otsuka’s studies of Kidney Failure, Chronic in search

Bristol-Myers Squibb in Kidney Failure, Chronic: 3 programs

  1. golcadomidephase 3
  2. admilparantphase 3
  3. mezigdomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Kidney Failure, Chronic in search

Lupus Erythematosus, Systemicboth · compare here

Otsuka in Lupus Erythematosus, Systemic: 1 program

  1. VIS171phase 1

Their studies: Otsuka’s studies of Lupus Erythematosus, Systemic in search

Bristol-Myers Squibb in Lupus Erythematosus, Systemic: 3 programs

  1. zolacabtagene autoleucelphase 3
  2. obexelimabphase 3
  3. deucravacitinibapproved, new study

Their studies: Bristol-Myers Squibb’s studies of Lupus Erythematosus, Systemic in search

Neoplasm Metastasisboth · compare here

Otsuka in Neoplasm Metastasis: 2 programs

  1. futibatinibphase 3
  2. zimberelimabphase 3

Their studies: Otsuka’s studies of Neoplasm Metastasis in search

Bristol-Myers Squibb in Neoplasm Metastasis: 2 programs

  1. adagrasibphase 3
  2. repotrectinibphase 3

Their studies: Bristol-Myers Squibb’s studies of Neoplasm Metastasis in search

Depressive Disorder, Majorboth · compare here

Otsuka in Depressive Disorder, Major: 2 programs

  1. ulotarontphase 3
  2. centanafadine hydrochloridephase 3

Their studies: Otsuka’s studies of Depressive Disorder, Major in search

Bristol-Myers Squibb in Depressive Disorder, Major: 1 program

  1. BMS-986511phase 2

Their studies: Bristol-Myers Squibb’s studies of Depressive Disorder, Major in search

Heart Failureboth · compare here

Otsuka in Heart Failure: 2 programs

  1. OPC 131461phase 2
  2. Tolvaptanapproved, new study

Their studies: Otsuka’s studies of Heart Failure in search

Bristol-Myers Squibb in Heart Failure: 1 program

  1. delocamtenphase 2

Their studies: Bristol-Myers Squibb’s studies of Heart Failure in search

Lung Neoplasmsboth · compare here

Otsuka in Lung Neoplasms: 1 program

  1. zipalertinibphase 3

Their studies: Otsuka’s studies of Lung Neoplasms in search

Bristol-Myers Squibb in Lung Neoplasms: 1 program

  1. navlimetostatphase 3

Their studies: Bristol-Myers Squibb’s studies of Lung Neoplasms in search

Lymphoma, B-Cellboth · compare here

Otsuka in Lymphoma, B-Cell: 1 program

  1. ARC-02phase 1

Their studies: Otsuka’s studies of Lymphoma, B-Cell in search

Bristol-Myers Squibb in Lymphoma, B-Cell: 1 program

  1. golcadomidephase 3

Their studies: Bristol-Myers Squibb’s studies of Lymphoma, B-Cell in search

Uterine Cervical Neoplasmsboth · compare here

Otsuka in Uterine Cervical Neoplasms: 1 program

  1. zimberelimabphase 3

Their studies: Otsuka’s studies of Uterine Cervical Neoplasms in search

Bristol-Myers Squibb in Uterine Cervical Neoplasms: 1 program

  1. imzokitugphase 2

Their studies: Bristol-Myers Squibb’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Otsuka 7 of 25 · Bristol-Myers Squibb 32 of 57 programs (22 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Bristol-Myers Squibb: 9).